NON-SMALL CELL LUNG CANCER

This early-phase study tested a new drug called SO-C101, either by itself or combined with the immunotherapy pembrolizumab, in 115 people with various advanced solid tumors (like lung, kidney, or skin cancer) that had stopped responding to standard treatments. The main goals were…

This early-stage study tested a new drug called PF-07921585, given alone or with another drug (sasanlimab), in 4 adults with advanced solid tumors like lung, bladder, kidney, or skin cancer. The main goal was to check safety and find the right dose. The study was stopped early, s…

This early-stage trial tested a new drug, MRTX0902, alone or with another drug (adagrasib) in 64 people with advanced solid tumors that have specific KRAS gene mutations. The goal was to check safety and how the body processes the drug. The study was stopped early, but the inform…

This early-phase study tested a new immunotherapy called IMU-201 in 24 adults with advanced non-small cell lung cancer. The treatment aims to help the body's immune system fight cancer by targeting a protein called PD-1. Some participants received IMU-201 alone, while others got …

This early-phase study tested a new drug called MGY825 in 41 adults with advanced non-small cell lung cancer that had specific genetic changes. The main goal was to check the drug's safety and find the right dose. The study was stopped early, so we don't have full results on how …

This study tested whether adding canakinumab to standard immunotherapy (pembrolizumab) and chemotherapy could help people with advanced non-small cell lung cancer live longer or slow tumor growth. It included over 670 participants who had not received prior treatment. The trial w…

This study tested whether giving a higher dose of radiation directly to the main tumor, while keeping standard doses to surrounding areas, is safe for people with non-small cell lung cancer. Six participants received targeted radiation plus standard chemotherapy. The goal was to …

This study tested a new drug called SAR444245 combined with other cancer treatments in 106 adults with advanced non-small cell lung cancer or pleural mesothelioma. The goal was to see if the combination shrank tumors. The trial was terminated early, so final results are limited.

This early-phase study tested whether adding high-dose vitamin C to the immunotherapy drug durvalumab could boost the immune system's attack on non-small cell lung cancer. Only one person participated before the study was stopped. The goal was to measure immune cell changes in tu…